$BTAIQ News

Teva makes stalking horse bid for BioXcel assets

Teva Pharmaceuticals to acquire BioXcel assets for up to $125m

What Is Teva Pharmaceutical Industries (TEVA) Gaining From This Bankruptcy Drug Deal?

BioXcel Stock Plunges: Chapter 11 Filing Triggers Teva Stalking Horse Bid

BioXcel Therapeutics Enters Asset Sale Agreement With Teva Pharmaceuticals

BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals

BioXcel Therapeutics Files Chapter 11 Bankruptcy, Estimates Liabilities Up To $500M Versus Assets As Low As $10M

BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Misses Revenue Estimates

What Makes BioXcel Therapeutics (BTAI) a New Buy Stock

BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting

BioXcel Presents New Data From Phase 3 SERENITY At-Home Trial Evaluating BXCL501 For Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia At 2026 ASCP Annual Meeting

BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates

BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy?

BioXcel Therapeutics, Inc. (BTAI) Discusses Commercial Launch Strategy and Market Opportunity for IGALMI in At-Home Setting Transcript

H.C. Wainwright Adjusts BioXcel Therapeutics, Inc. (BTAI) Outlook Following Capital Structure Concerns

BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting

How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Promise And Dilution Risks

BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions

BioXcel Therapeutics Kicks Off DoD-Funded Phase 2a Study Of BXCL501 For Acute Stress Reactions, Led By UNC Institute For Trauma Recovery